APEX1 and neoplasm: The APE1-centered hypothesis presented herein provides a framework for treatment personalization: single-agent chemotherapy suffices for low-APE1 ESCC, whereas high-APE1 cases warrant combinatorial targeting of both tumor invasion and immune evasion pathways (Graphic Abstract).